Patients lose “spectacular” amounts of weight on Eli Lilly’s GLP-1 medicine. But doctors say with greater potency comes greater risk.
May 29, 2026 at 5:00 a.m. EDTYesterday at 5:00 a.m. EDT
The headquarters of Eli Lilly in Indianapolis. (Scott Olson/Getty Images)
Eli Lilly this month unveiled startling new data that showed an experimental weight-loss drug caused people with obesity to shed, on average, 28 percent of their body weight — a substantial step up in potency from the existing crop of GLP-1 medicines.